文献速递肝病消化道肿瘤与早癌

SHP2阻断联合索拉非尼克服肝细胞癌适应性耐药

Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2020-03-31

该研究探讨肝细胞癌对索拉非尼适应性耐药的机制。在耐药细胞系和患者来源异种移植瘤中发现SHP2显著上调,索拉非尼通过激活AXL、EGFR、EPHA2和IGF1R等RTK导致MEK/ERK和AKT再激活。SHP099抑制SHP2可阻断该负反馈机制,在体外和体内恢复索拉非尼敏感性。

要点

  • SHP2在索拉非尼耐药的HCC细胞和PDX中显著上调
  • 索拉非尼诱导RTK激活导致MEK/ERK和AKT通路再激活
  • SHP099联合索拉非尼可克服适应性耐药并抑制肿瘤生长

核心结论

  • SHP099阻断SHP2联合索拉非尼通过抑制RTK诱导的MEK/ERK和AKT再激活来减弱适应性耐药
  • SHP099联合索拉非尼可能是治疗HCC的安全策略

研究设计与样本

  • 研究使用索拉非尼耐药细胞系、患者来源异种移植瘤、类器官培养、异种移植瘤和基因工程HCC模型

主要发现

  • SHP2在建立的索拉非尼耐药细胞系和患者来源异种移植瘤中显著上调
  • 索拉非尼治疗激活AXL、EGFR、EPHA2和IGF1R等RTK,导致RAS/MEK/ERK和AKT再激活
  • SHP099在体外通过阻断负反馈机制消除HCC细胞系和类器官培养中的索拉非尼耐药
  • SHP099的增敏效应也由诱导细胞衰老介导
  • SHP099联合索拉非尼在异种移植瘤和基因工程HCC模型中高效

临床怎么用

  • 对于索拉非尼治疗的HCC患者,SHP2表达上调可能提示适应性耐药
  • SHP099联合索拉非尼可能成为克服耐药的潜在治疗策略

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The survival benefit of sorafenib for patients with hepatocellular carcinoma (HCC) is unsatisfactory due to the development of adaptive resistance. Increasing evidence has demonstrated that drug resistance can be acquired by cancer cells by activating a number of signaling pathways through receptor tyrosine kinases (RTKs); nevertheless, the detailed mechanism for the activation of these alternative pathways is not fully understood. APPROACH AND RESULTS: Given the physiological role of Src homology 2 domain-containing phosphatase 2 (SHP2) as a downstream effector of many RTKs for activation of various signaling cascades, we first found that SHP2 was markedly up-regulated in our established sorafenib-resistant cell lines as well as patient-derived xenografts. Upon sorafenib treatment, adaptive resistance was acquired in HCC cells through activation of RTKs including AXL, epidermal growth factor receptor, EPH receptor A2, and insulin-like growth factor 1 receptor, leading to RAS/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK), and AKT reactivation. We found that the SHP2 inhibitor SHP099 abrogated sorafenib resistance in HCC cell lines and organoid culture in vitro by blocking this negative feedback mechanism. Interestingly, this sensitization effect was also mediated by induction of cellular senescence. SHP099 in combination with sorafenib was highly efficacious in the treatment of xenografts and genetically engineered models of HCC. CONCLUSIONS: SHP2 blockade by SHP099 in combination with sorafenib attenuated the adaptive resistance to sorafenib by impeding RTK-induced reactivation of the MEK/ERK and AKT signaling pathways. SHP099 in combination with sorafenib may be a safe therapeutic strategy against HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Leung CON, Tong M, Chung KPS, et al. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma. Hepatology. 2020. PMID: 31610028. doi:10.1002/hep.30989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。